NeoGenomics, Inc.: NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR MRD and InVisionFirst-Lung Tests at the 2022 ASCO Annual Meeting

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced

Related Keywords

Fort Myers ,Florida ,United States ,Georgia ,Tampa ,North Carolina ,United Kingdom ,Texas ,Research Triangle Park ,Atlanta ,California ,San Diego ,Tennessee ,Singapore ,Houston ,Aliso Viejo ,Cambridge ,Cambridgeshire ,Switzerland ,American ,Charlie Eidson ,Karen Chandler Smith ,Inivata Invision ,Doug Brown ,Company Invisionfirst ,Cancer Research United Kingdom Cambridge Institute ,American Society Of Clinical Oncology ,Neogenomics Inc ,Inivata Limited ,Company Pharma Services Division ,Nasdaq ,University Of Cambridge ,While The Company ,Company Annual Report On Form ,Corporate Development ,Consilium Strategic Communications ,American Society ,Clinical Oncology ,Annual Meeting ,Chief Medical Officer ,Saturday June ,Liquid Biopsy ,Minimal Residual Disease Detection ,Neck Squamous Cell Carcinoma ,Pharma Services Division ,Privacy Practices ,Breakthrough Device Designation ,Private Securities Litigation Reform Act ,Annual Report ,Corporate Development Officer ,Investor Relations ,Media Contacts ,Neogenomics ,Liquid ,Biopsy ,Ubsidiary ,Inivata ,Collaborators ,Present ,Data ,Urther ,Invalidating ,Application ,Radar ,Nvisionfirst ,Young ,Tests ,022 ,Disco ,Nnual ,Meeting ,